Best Peptides for Weight Loss — Evidence Review
Weight loss is the strongest peptide use case in clinical medicine. The incretin-agonist class — GLP-1, dual GIP/GLP-1, and triple agonists — has transformed obesity treatment since 2017. Outcomes…
Weight loss is the strongest peptide use case in clinical medicine. The incretin-agonist class — GLP-1, dual GIP/GLP-1, and triple agonists — has transformed obesity treatment since 2017. Outcomes that previously required bariatric surgery are now achievable with subcutaneous injection.
This guide ranks by evidence weight and clinical magnitude.
Strongest evidence
Tirzepatide (Mounjaro / Zepbound)
Dual GIP/GLP-1 receptor agonist. SURMOUNT-1 reported 22.5% mean total body weight loss at 15 mg over 72 weeks in non-diabetic adults with obesity. SURMOUNT-2 reported similar magnitude in T2D patients (still substantial but slightly smaller than non-diabetic). Head-to-head against semaglutide in SURMOUNT-5 favored tirzepatide.
Side effect profile: GI symptoms (nausea, vomiting, diarrhea, constipation) particularly during titration. Standard 4–5 month titration to target dose. Hypoglycemia risk is low unless stacked with insulin or sulfonylureas.
Semaglutide (Wegovy / Ozempic / Rybelsus)
GLP-1 receptor agonist. STEP trial program reported ~15% mean weight loss over 68 weeks. STEP 5 demonstrated durability over 104 weeks. SELECT cardiovascular outcomes trial established CV benefit at the 2.4 mg weekly dose in overweight/obese non-diabetic patients with CV disease.
Lower weight-loss magnitude than tirzepatide but more post-marketing data and a clearer cardiovascular outcome story. Practical preference depends on insurance, cost, and side-effect tolerance.
Retatrutide
Triple agonist (GIP, GLP-1, glucagon). Phase 2 obesity trial (Jastreboff et al., NEJM 2023) reported 24.2% mean weight reduction at 48 weeks at the 12 mg dose — the largest single-trial weight-loss number in the class. The TRIUMPH Phase 3 program is ongoing.
If Phase 3 confirms Phase 2 numbers, retatrutide will set the new ceiling for non-surgical weight loss. Approval timeline likely 2026–2027.
Liraglutide (Saxenda)
First-generation GLP-1 (daily injection). ~6–8% mean weight loss in trials — smaller than weekly agonists. Largely superseded for new starts but remains useful when weekly dosing isn't tolerated and when faster pharmacokinetic clearance is needed.
CagriSema (Cagrilintide + Semaglutide)
Combination of an amylin analog (cagrilintide) and semaglutide. Phase 2 reported 15.6% weight loss at 32 weeks; REDEFINE 1 Phase 3 reported 22.7% at 68 weeks — competitive with tirzepatide. Approval pending.
Supporting cast
Tesamorelin
Visceral-fat-selective GHRH analog approved for HIV-associated lipodystrophy. Doesn't produce overall weight loss comparable to GLP-1 agonists but reduces visceral adipose tissue specifically. Adjunctive use case for visceral-predominant adiposity.
What the evidence does not support
- "Weight-loss peptide stacks" combining 3+ peptides without controlled-trial support
- BPC-157, CJC-1295, ipamorelin, or GH secretagogues as primary weight-loss therapy
- Use during pregnancy or pregnancy-planning windows (manufacturer washouts apply)
- Use in patients with personal/family history of MTC or MEN2 syndrome (FDA boxed warning)
Practical considerations
GLP-1 agonist therapy for weight management is most successful when paired with:
- Resistance training (preserves lean mass during caloric deficit)
- Adequate protein intake (1.2–1.6 g/kg ideal body weight)
- Sustained dietary modification (post-discontinuation regain is the primary durability concern)
- Realistic expectations on side-effect titration timeline
Where to source
- Tirzepatide vendor rankings — 38 ranked vendors
- Semaglutide vendor rankings — 31 ranked vendors
- Retatrutide vendor rankings — 24 ranked vendors
Branded products (Wegovy, Zepbound, Ozempic, Mounjaro) are preferred where insurance allows. The compounded landscape has tightened with FDA enforcement post-shortage.
What we don't know
- Long-term durability beyond 5 years of continuous use
- Optimal sequencing (semaglutide → tirzepatide → retatrutide as approvals stack up)
- Strategies to maintain weight loss after discontinuation (most patients regain substantially)
- Whether triple agonists outperform dual agonists at equivalent weight loss on metabolic endpoints
Methodology
Read the full methodology.
This page is educational. GLP-1 therapy is a clinical decision involving comorbidity assessment, contraindication screening, and ongoing monitoring with a treating physician.